Open Angle Glaucoma Clinical Trial
Official title:
A First in Human Clinical Trial to Evaluate the Safety and Effectiveness of the STREAMLINE™ SURGICAL SYSTEM in Patients With Open-Angle Glaucoma
Verified date | May 2023 |
Source | New World Medical, Inc. |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The purpose of this study is to evaluate the safety and Intraocular pressure lowering effectiveness of the Streamline™ Surgical System.
Status | Completed |
Enrollment | 42 |
Est. completion date | September 21, 2022 |
Est. primary completion date | September 21, 2022 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 22 Years and older |
Eligibility | Inclusion Criteria: Subjects must meet all the following criteria in order to be eligible for participation in this study: 1. Subjects qualifying for cataract surgery 2. Subjects with diagnosis of open-angle glaucoma in at least one eye with unmedicated IOP of 21-36 mmHg. Exclusion Criteria: - Subjects are ineligible for participation in this study if s/he meets any of the following criteria: 1. Patients who could not be washed-out of IOP-lowering medications. . |
Country | Name | City | State |
---|---|---|---|
Mexico | Dr. Gabriel S. Lazcano Gomez | Puerto Mexico |
Lead Sponsor | Collaborator |
---|---|
New World Medical, Inc. |
Mexico,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Proportion of unmedicated eyes with intraocular pressure (IOP) reduction of =20% | Descriptive | From Baseline at Month 12 | |
Secondary | Changes from baseline in intraocular pressure (IOP) | Exploratory analysis | From Baseline at Month 12 | |
Secondary | Changes from baseline in number of IOP lowering medications | Exploratory analysis | From Baseline at Month 12 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03284853 -
Safety and Efficacy Study of PG324 (Netarsudil/Latanoprost 0.02% / 0.005%) Ophthalmic Solution Compared to GANFORT® Ophthalmic Solution in Open Angle Glaucoma or Ocular Hypertension
|
Phase 3 | |
Terminated |
NCT03611530 -
CoQun Study - (COQUN): a Study to Evaluate the Effects of CoQun in Patients Affected by Open-angle Glaucoma
|
N/A | |
Not yet recruiting |
NCT06441643 -
Next Generation Rocklatan
|
Phase 2 | |
Not yet recruiting |
NCT02868502 -
Different Glaucoma Treatments Effect on Intraocular Pressure Fluctuation With Postural Change in Eyes With Open-angle Glaucoma
|
N/A | |
Completed |
NCT02628223 -
180 Degree vs. 360 Degree Selective Laser Trabeculoplasty as Initial Therapy for Glaucoma
|
N/A | |
Completed |
NCT02272569 -
STARflo European Safety and Efficacy Study
|
N/A | |
Completed |
NCT01936389 -
A Prospective Study to Assess the Hypotensive Efficacy of Rho-Kinase Inhibitor AR-12286 Ophthalmic Solution 0.5% and 0.7% in Patients With Exfoliation Syndrome and Ocular Hypertension or Glaucoma
|
Phase 2 | |
Completed |
NCT00941525 -
Central Corneal Thickness and 24-hour Fluctuation of Intraocular Pressure
|
Phase 4 | |
Completed |
NCT00539526 -
Evaluation of Hyperemia With the Use of Ocular Prostaglandin Analogues
|
Phase 4 | |
Completed |
NCT00121147 -
Additivity Study: Additive Effect on Eye Pressure of Azopt and Alphagan P to Travatan
|
N/A | |
Active, not recruiting |
NCT05035394 -
Swedish Microinvasive Glaucoma Surgery Study (SMIGS)
|
N/A | |
Completed |
NCT03450629 -
Evaluation of Safety and Efficacy of PDP-716
|
Phase 3 | |
Active, not recruiting |
NCT06061718 -
Travoprost Intraocular Implant in Conjunction With Cataract Surgery
|
Phase 3 | |
Recruiting |
NCT05241938 -
PSLT Compared to Prostaglandin Analogue Eye Drops
|
N/A | |
Completed |
NCT01342406 -
Effects of Selective Laser Trabeculoplasty on Aqueous Humor Dynamics
|
||
Completed |
NCT02250612 -
SYL040012, Treatment for Open Angle Glaucoma
|
Phase 2 | |
Completed |
NCT01937299 -
Effect of SIMBRINZA® Suspension as an Added Therapy to TRAVATAN Z®
|
Phase 4 | |
Completed |
NCT01937312 -
Effect of SIMBRINZA® Suspension as an Added Therapy to a Prostaglandin Analogue
|
Phase 4 | |
Terminated |
NCT01983579 -
TF (SENSIMED Triggerfish) in Intraocular Anti-VEGF (Vascular Endothelial Growth Factor) Injection
|
Phase 4 | |
Completed |
NCT01229982 -
A Study Evaluating the Latanoprost Punctal Plug Delivery System (L-PPDS) in Subjects With Ocular Hypertension or Open-Angle Glaucoma
|
Phase 2 |